induction phase1

Phase 3Small molecule

Genmab

induction phase1 is one of 429 small molecule programs targeting Ependymoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

428

Competitors

Pipeline

Status by Indication[3][1]

Indication

EpendymomaActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Lymphoblastic LymphomaActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

LeukemiaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

EpendymomaPhase 2

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Lymphoblastic LymphomaPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

LeukemiaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

induction phase1

Genmab

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

Lexiscan

Astellas

Preclinical

1 6

Adenocard

Astellas

Preclinical

1 7

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 8

Spravato

WWim Janssens

Preclinical

2 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Concurrent Chemoradiotherapy

NCT06139419

Q4 2026

Phase 2Active, not recruiting

Esophageal Squamous Cell Carcinoma

NCT06281886

Phase 2/3Active, not recruiting

Medulloblastoma

NCT02066220

Q3 2027

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT05062005

Q4 2028

N/ANot yet recruiting

Nasopharyngeal Carcinoma

NCT05622474

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma5 trials

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT05304468·452 enrolled

Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05232552·37 enrolled

ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma

Recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 3·NCT05062005·447 enrolled

Show 2 more trials

Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

Unknown status·SShanghai Proton and Heavy Ion Center·Phase 2·NCT04143984·146 enrolled

A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy

Not yet recruiting·SSun Yat-sen University·N/A·NCT05622474·236 enrolled

Induction Chemotherapy3 trials

Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors

Terminated·MMemorial Sloan Kettering Cancer Center·N/A·NCT02519712·4 enrolled

Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

Recruiting·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT06207981·310 enrolled

Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study

Unknown status·FFeng Jing·Phase 2·NCT02187315·160 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT06281886·170 enrolled

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06912074·134 enrolled

Lymphoblastic Lymphoma1 trial

Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

Unknown status·SSun Yat-sen University·Phase 2·NCT02396043·50 enrolled

Ependymoma1 trial

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT00602667·293 enrolled

19 more indications

Gastric Cancer1 trial

Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients

Completed·—··NCT02454647·46 enrolled

Esophageal Cancer1 trial

PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer

Recruiting·MMedical College of Wisconsin·Phase 2·NCT06906887·50 enrolled

Breast Cancer1 trial

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT01491737·258 enrolled

Acute Myeloid Leukemia1 trial

Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)

Completed·SSeoul National University Hospital·Phase 2·NCT01247493·108 enrolled

Myeloid Neoplasm1 trial

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Completed·HHospital Israelita Albert Einstein·Phase 2·NCT02084563·455 enrolled

Leukemia1 trial

A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Withdrawn· Eisai logo

Eisai·Phase 2·NCT00943553

Infusion1 trial

Post Transplant Donor Lymphocyte Infusion

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00167180·57 enrolled

Surgery1 trial

A Study of Tongue Conservation Surgery for Oral Tongue Cancer

Terminated·TTaipei Veterans General Hospital, Taiwan·Phase 2·NCT03161548·23 enrolled

Esophageal Squamous Carcinoma1 trial

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Active, not recruiting·SSun Yat-sen University·Phase 1·NCT06020885·18 enrolled

Stage III1 trial

SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00002735·68 enrolled

Non-Small Cell Lung Cancer1 trial

Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 3·NCT01850303·632 enrolled

Medulloblastoma1 trial

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Active, not recruiting·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2/3·NCT02066220·360 enrolled

Trial1 trial

Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC

Recruiting·—·Phase 3·NCT06846450·470 enrolled

Chemotherapy1 trial

Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04296747·100 enrolled

Concurrent Chemoradiotherapy1 trial

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT06139419·114 enrolled

Squamous Cell Carcinoma1 trial

Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma

Not yet recruiting·NNYU Langone Health·Phase 1/2·NCT07428148·60 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07259473·15 enrolled

Lung Cancer1 trial

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Terminated· Genmab logo

Genmab·Phase 2·NCT00460551·13 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Unknown status·—·Phase 3·NCT03815903·434 enrolled

Sources

References

[1]
ClinicalTrials.gov — 31 trial records for induction phase1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — induction phase1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for induction phase1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Genmab

induction phase1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2027

Q4 2028

Trials by Indication[1]

Nasopharyngeal Carcinoma5 trials

Induction Chemotherapy3 trials

Esophageal Squamous Cell Carcinoma2 trials

Lymphoblastic Lymphoma1 trial

Ependymoma1 trial

Gastric Cancer1 trial

Esophageal Cancer1 trial

Breast Cancer1 trial

Acute Myeloid Leukemia1 trial

Myeloid Neoplasm1 trial

Leukemia1 trial

Infusion1 trial

Surgery1 trial

Esophageal Squamous Carcinoma1 trial

Stage III1 trial

Non-Small Cell Lung Cancer1 trial

Medulloblastoma1 trial

Trial1 trial

Chemotherapy1 trial

Concurrent Chemoradiotherapy1 trial

Squamous Cell Carcinoma1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Lung Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News